경피증 진단 및 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 8.5%의 성장률(CAGR)로 41억 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 정밀의료의 부상, 새로운 생물학적 치료법 개발, 줄기세포 연구 확대, 약물전달 시스템 개선, 희귀질환 치료제 규제 지원 등 여러 가지 요인에 기인하는 것으로 보입니다. 이 기간의 주요 동향으로는 AI를 활용한 진단 알고리즘, 유전자 프로파일링을 위한 차세대 시퀀싱, 나노기술을 활용한 약물전달, 실시간 모니터링을 위한 웨어러블 바이오센서, 조직 재생을 위한 3차원(3D) 바이오프린팅 등을 들 수 있습니다. 프린팅 등을 들 수 있습니다.
자가면역질환의 유병률 증가는 경피증 진단 및 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 면역체계가 자신의 건강한 세포를 잘못 공격하여 발생하는 질환입니다. 자가면역질환의 유병률은 유전적 소인으로 인해 증가하는 추세입니다. 특정 유전적 돌연변이가 면역체계의 활동에 영향을 미쳐 결합조직의 이상을 유발하기 때문입니다. 경피증 진단 및 치료제는 조기 발견을 가능하게 하고, 임상적 의사결정을 간소화하는 개별화된 치료 전략을 촉진하여 자가면역질환 관리를 개선하고, 궁극적으로 환자의 결과와 삶의 질을 향상시킬 수 있습니다. 예를 들어, 2024년 6월 호주 보건 복지 연구소(Australian Institute of Health and Welfare)는 2022년 51만 4,000명(2.0%)이 류마티스 관절염을 앓고 있다고 보고했습니다. 또한, 이 질환으로 인한 사망자는 1,322명으로 2022년 전체 사망자의 0.7%를 차지할 것으로 예상했습니다. 이러한 수치는 경피증 진단 및 치료제 시장을 주도하는 질병 부담의 증가를 강조하고 있습니다.
경피증 진단 및 치료제 시장의 주요 기업들은 질병 관리를 강화하고 환자 예후를 개선하기 위해 완전 인간 CD19 CAR T 세포 치료제와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 2023년 10월, 미국 바이오 제약회사 카이바나 테라퓨틱스는 완전 인간 CD19 CAR T세포 치료제인 KYV-101의 신약 임상시험 허가 신청을 FDA로부터 승인받았습니다. 본 치료제는 미만성 피부 전신 경화증(경피증) 치료를 목적으로 하며, KYSA-5 시험에서는 질병 진행에 관여하는 B세포를 표적으로 하여 자가면역질환 치료에 대한 안전성과 유효성을 평가할 예정입니다. 이 치료법은 면역체계를 재설정하여 경피증 환자의 예후를 개선하는 것을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 경피증 진단 및 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 경피증 진단 및 치료제 시장 : 성장률 분석
- 세계의 경피증 진단 및 치료제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 경피증 진단 및 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 경피증 진단 및 치료제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 경피증 진단 및 치료제 시장 약제 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 코르티코스테로이드
- 면역억제제
- 엔도텔린 수용체 길항제
- 칼슘 채널 차단제
- 포스포디에스테라제 5형(PDE-5) 억제제
- 킬레이트제
- 프로스타사이클린 유사체
- 기타 약물 종류
- 세계의 경피증 진단 및 치료제 시장 진단 검사 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 혈액 검사
- 영상 기술
- 피부 생검
- 폐기능 검사
- 심전도와 심에코도
- 세계의 경피증 진단 및 치료제 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 전신경화증
- 국소성 경피증
- 세계의 경피증 진단 및 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 주사제
- 토픽
- 세계의 경피증 진단 및 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 진단 센터
- 민간 연구소
- 정부 연구소
- 기타 최종사용자
- 세계의 경피증 진단 및 치료제 시장 코르티코스테로이드 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 프레드니손
- 메틸프레드니솔론
- 덱사메타손
- 세계의 경피증 진단 및 치료제 시장멘역 억제제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 메토트렉세이트
- 마이코페놀레이트 모페틸
- 아자티오프린
- 사이클로포스파미드
- 세계의 경피증 진단 및 치료제 시장 엔도텔린 수용체 길항제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 보센탄
- 암브리센탄
- 마시텐탄
- 세계의 경피증 진단 및 치료제 시장 칼슘 채널 차단제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 니페디핀
- 암로디핀
- 딜티아젬
- 세계의 경피증 진단 및 치료제 시장 포스포디에스테라제 5형 억제제(PDE-5) 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 실데나필
- 타다라필
- 바데나필
- 세계의 경피증 진단 및 치료제 시장 킬레이트제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- D-페니실라민
- 데페록사민
- 세계의 경피증 진단 및 치료제 시장 프로스타사이클린 유사체 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 에포프로스테놀
- 일로프로스트
- 트레프로스티닐
- 세계의 경피증 진단 및 치료제 시장, 기타 약물 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 리툭시맙(단클론항체)
- 아바타셉트(T세포 변조기)
- 토실리주맙(IL-6 억제제)
제7장 지역별·국가별 분석
- 세계의 경피증 진단 및 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 경피증 진단 및 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 경피증 진단 및 치료제 시장 : 경쟁 구도
- 경피증 진단 및 치료제 시장 : 기업 개요
- Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- GSK plc
- Boehringer Ingelheim International GmbH
- Lupin Diagnostics Limited
- Galapagos NV
- Cumberland Pharmaceuticals Inc.
- Inventiva S.A.
- Redx Pharma plc
- Kadmon Holdings Inc.
- Certa Therapeutics Pty Ltd
- Corbus Pharmaceuticals Holdings Inc.
- Emerald Health Pharmaceuticals Inc.
- aTyr Pharma Inc.
- MediciNova Inc.
- MitogenDx Inc.
- arGentis Pharmaceuticals LLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 경피증 진단 및 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 경피증 진단 및 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 경피증 진단 및 치료제 시장 2029 : 성장 전략
제36장 부록
ksm
Scleroderma diagnostics and therapeutics encompass advanced testing methods and targeted treatments aimed at detecting and managing scleroderma, a chronic autoimmune disorder that causes the hardening and tightening of the skin and connective tissues. These methods are used to identify symptoms such as Raynaud's phenomenon, skin thickening, and involvement of internal organs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main drug types for scleroderma diagnostics and therapeutics include corticosteroids, immunosuppressive agents, endothelin receptor antagonists, calcium channel blockers, phosphodiesterase type 5 (PDE-5) inhibitors, chelating agents, prostacyclin analogues, and others. Corticosteroids are steroid hormones that help reduce inflammation and suppress the immune system. Diagnostic tests for scleroderma include blood tests, imaging techniques, skin biopsies, pulmonary function tests, electrocardiograms, and echocardiograms, which are categorized into systemic scleroderma and localized scleroderma based on their indications. These treatments and tests are administered via various routes, such as oral, injectable, and topical, and are used by a range of end-users, including hospitals, diagnostic centers, private laboratories, government laboratories, and others.
The scleroderma diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides scleroderma diagnostics and therapeutics market statistics, including scleroderma diagnostics and therapeutics industry global market size, regional shares, competitors with a scleroderma diagnostics and therapeutics market share, detailed scleroderma diagnostics and therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma diagnostics and therapeutics industry. This scleroderma diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The scleroderma diagnostics and therapeutics market size has grown strongly in recent years. It will grow from$2.71 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to several factors, including the discovery of antinuclear antibodies, the introduction of pulmonary function tests, increased awareness of autoimmune diseases, the establishment of funding programs for rare diseases, and the expansion of clinical trial networks.
The scleroderma diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to$4.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth during the forecast period can be attributed to several factors, including the rise of precision medicine, the development of novel biologic therapies, the expansion of stem cell research, improved drug delivery systems, and regulatory support for orphan drugs. Key trends during this period include AI-powered diagnostic algorithms, next-generation sequencing for genetic profiling, nanotechnology-based drug delivery, wearable biosensors for real-time monitoring, and three-dimensional (3D) bioprinting for tissue regeneration.
The increasing prevalence of autoimmune diseases is expected to drive the growth of the scleroderma diagnostics and therapeutics market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells. The prevalence of autoimmune diseases is on the rise due to genetic predisposition, as certain genetic variations influence immune system activity and cause abnormalities in connective tissues. Scleroderma diagnostics and therapeutics help improve autoimmune disease management by enabling early detection and facilitating personalized treatment strategies that streamline clinical decision-making, ultimately improving patient outcomes and quality of life. For instance, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 (2.0%) people were living with rheumatoid arthritis in 2022, which contributed to 2.0% of the total disease burden. Additionally, there were 1,322 deaths from the condition, accounting for 0.7% of all deaths in 2022. These figures highlight the growing disease burden, propelling the market for scleroderma diagnostics and therapeutics.
Leading companies in the scleroderma diagnostics and therapeutics market are focusing on developing innovative treatments, such as fully human CD19 CAR T-cell therapy, to enhance disease management and improve patient outcomes. CD19 CAR T-cell therapy is a form of immunotherapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) targeting CD19, a protein found on B cells. In October 2023, Kyverna Therapeutics Inc., a U.S.-based biopharmaceutical company, received FDA clearance for its Investigational New Drug (IND) application for KYV-101, a fully human CD19 CAR T-cell therapy. The therapy is designed for the treatment of diffuse cutaneous systemic sclerosis (scleroderma), and the KYSA-5 trial will assess its safety and efficacy in treating autoimmune diseases by targeting B cells involved in disease progression. This therapy aims to reset the immune system and enhance patient outcomes in scleroderma.
In October 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen seeks to strengthen its portfolio in rare autoimmune and inflammatory diseases by leveraging Horizon Therapeutics' expertise and innovative drug pipeline. Horizon Therapeutics, an Ireland-based biotechnology company, specializes in developing treatments for scleroderma, focusing on innovative therapies that target fibrosis and regulate the immune system.
Major players in the scleroderma diagnostics and therapeutics market are Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., GSK plc, Boehringer Ingelheim International GmbH, Lupin Diagnostics Limited, Galapagos NV, Cumberland Pharmaceuticals Inc., Inventiva S.A., Redx Pharma plc, Kadmon Holdings Inc., Certa Therapeutics Pty Ltd, Corbus Pharmaceuticals Holdings Inc., Emerald Health Pharmaceuticals Inc., aTyr Pharma Inc., MediciNova Inc., MitogenDx Inc., and arGentis Pharmaceuticals LLC.
North America was the largest region in the scleroderma diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scleroderma diagnostics and therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the scleroderma diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The scleroderma diagnostics and therapeutics market includes revenues earned by entities by providing services such as advanced diagnostic imaging and laboratory testing, biomarker and genetic testing, targeted therapeutic development, personalized treatment planning, and remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Scleroderma Diagnostics And Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on scleroderma diagnostics and therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for scleroderma diagnostics and therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleroderma diagnostics and therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Corticosteroids; Immunosuppressive Agents; Endothelin Receptor Antagonists; Calcium Channel Blockers; Phosphodiesterase Type 5 (PDE-5) Inhibitors; Chelating Agents; Prostacyclin Analogues; Other Drug Types
- 2) By Diagnostic Test Type: Blood Tests; Imaging Techniques; Skin Biopsy; Pulmonary Function Tests; Electrocardiogram And Echocardiogram
- 3) By Indication: Systemic Scleroderma; Localized Scleroderma
- 4) By Route Of Administration: Oral; Injectable; Topical
- 5) By End-User: Hospitals; Diagnostic Centers; Private Laboratories; Government Laboratories; Other End-Users
- Subsegments:
- 1) By Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
- 2) By Immunosuppressive Agents: Methotrexate; Mycophenolate Mofetil; Azathioprine; Cyclophosphamide
- 3) By Endothelin Receptor Antagonists: Bosentan; Ambrisentan; Macitentan
- 4) By Calcium Channel Blockers: Nifedipine; Amlodipine; Diltiazem
- 5) By Phosphodiesterase Type 5 Inhibitors (Pde-5) Inhibitors: Sildenafil; Tadalafil; Vardenafil
- 6) By Chelating Agents: D-Penicillamine; Deferoxamine
- 7) By Prostacyclin Analogues: Epoprostenol; Iloprost; Treprostinil
- 8) By Other Drug Types: Rituximab (Monoclonal Antibody); Abatacept (T-Cell Modulator); Tocilizumab (Il-6 Inhibitor)
- Companies Mentioned: Johnson and Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Scleroderma Diagnostics And Therapeutics Market Characteristics
3. Scleroderma Diagnostics And Therapeutics Market Trends And Strategies
4. Scleroderma Diagnostics And Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Scleroderma Diagnostics And Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Scleroderma Diagnostics And Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Scleroderma Diagnostics And Therapeutics Market Growth Rate Analysis
- 5.4. Global Scleroderma Diagnostics And Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Scleroderma Diagnostics And Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Scleroderma Diagnostics And Therapeutics Total Addressable Market (TAM)
6. Scleroderma Diagnostics And Therapeutics Market Segmentation
- 6.1. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroids
- Immunosuppressive Agents
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Phosphodiesterase Type 5 (PDE-5) Inhibitors
- Chelating Agents
- Prostacyclin Analogues
- Other Drug Types
- 6.2. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Blood Tests
- Imaging Techniques
- Skin Biopsy
- Pulmonary Function Tests
- Electrocardiogram And Echocardiogram
- 6.3. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Systemic Scleroderma
- Localized Scleroderma
- 6.4. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- Topical
- 6.5. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Diagnostic Centers
- Private Laboratories
- Government Laboratories
- Other End-Users
- 6.6. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prednisone
- Methylprednisolone
- Dexamethasone
- 6.7. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Immunosuppressive Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Methotrexate
- Mycophenolate Mofetil
- Azathioprine
- Cyclophosphamide
- 6.8. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Endothelin Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bosentan
- Ambrisentan
- Macitentan
- 6.9. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nifedipine
- Amlodipine
- Diltiazem
- 6.10. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Phosphodiesterase Type 5 Inhibitors (PDE-5) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Sildenafil
- Tadalafil
- Vardenafil
- 6.11. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Chelating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- D-Penicillamine
- Deferoxamine
- 6.12. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Prostacyclin Analogues, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Epoprostenol
- Iloprost
- Treprostinil
- 6.13. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rituximab (Monoclonal Antibody)
- Abatacept (T-Cell Modulator)
- Tocilizumab (IL-6 Inhibitor)
7. Scleroderma Diagnostics And Therapeutics Market Regional And Country Analysis
- 7.1. Global Scleroderma Diagnostics And Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Scleroderma Diagnostics And Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market
- 8.1. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Scleroderma Diagnostics And Therapeutics Market
- 9.1. China Scleroderma Diagnostics And Therapeutics Market Overview
- 9.2. China Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Scleroderma Diagnostics And Therapeutics Market
- 10.1. India Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Scleroderma Diagnostics And Therapeutics Market
- 11.1. Japan Scleroderma Diagnostics And Therapeutics Market Overview
- 11.2. Japan Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Scleroderma Diagnostics And Therapeutics Market
- 12.1. Australia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Scleroderma Diagnostics And Therapeutics Market
- 13.1. Indonesia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Scleroderma Diagnostics And Therapeutics Market
- 14.1. South Korea Scleroderma Diagnostics And Therapeutics Market Overview
- 14.2. South Korea Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Scleroderma Diagnostics And Therapeutics Market
- 15.1. Western Europe Scleroderma Diagnostics And Therapeutics Market Overview
- 15.2. Western Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Scleroderma Diagnostics And Therapeutics Market
- 16.1. UK Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Scleroderma Diagnostics And Therapeutics Market
- 17.1. Germany Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Scleroderma Diagnostics And Therapeutics Market
- 18.1. France Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Scleroderma Diagnostics And Therapeutics Market
- 19.1. Italy Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Scleroderma Diagnostics And Therapeutics Market
- 20.1. Spain Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Scleroderma Diagnostics And Therapeutics Market
- 21.1. Eastern Europe Scleroderma Diagnostics And Therapeutics Market Overview
- 21.2. Eastern Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Scleroderma Diagnostics And Therapeutics Market
- 22.1. Russia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Scleroderma Diagnostics And Therapeutics Market
- 23.1. North America Scleroderma Diagnostics And Therapeutics Market Overview
- 23.2. North America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Scleroderma Diagnostics And Therapeutics Market
- 24.1. USA Scleroderma Diagnostics And Therapeutics Market Overview
- 24.2. USA Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Scleroderma Diagnostics And Therapeutics Market
- 25.1. Canada Scleroderma Diagnostics And Therapeutics Market Overview
- 25.2. Canada Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Scleroderma Diagnostics And Therapeutics Market
- 26.1. South America Scleroderma Diagnostics And Therapeutics Market Overview
- 26.2. South America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Scleroderma Diagnostics And Therapeutics Market
- 27.1. Brazil Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Scleroderma Diagnostics And Therapeutics Market
- 28.1. Middle East Scleroderma Diagnostics And Therapeutics Market Overview
- 28.2. Middle East Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Scleroderma Diagnostics And Therapeutics Market
- 29.1. Africa Scleroderma Diagnostics And Therapeutics Market Overview
- 29.2. Africa Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Scleroderma Diagnostics And Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Scleroderma Diagnostics And Therapeutics Market Competitive Landscape
- 30.2. Scleroderma Diagnostics And Therapeutics Market Company Profiles
- 30.2.1. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Scleroderma Diagnostics And Therapeutics Market Other Major And Innovative Companies
- 31.1. GSK plc
- 31.2. Boehringer Ingelheim International GmbH
- 31.3. Lupin Diagnostics Limited
- 31.4. Galapagos NV
- 31.5. Cumberland Pharmaceuticals Inc.
- 31.6. Inventiva S.A.
- 31.7. Redx Pharma plc
- 31.8. Kadmon Holdings Inc.
- 31.9. Certa Therapeutics Pty Ltd
- 31.10. Corbus Pharmaceuticals Holdings Inc.
- 31.11. Emerald Health Pharmaceuticals Inc.
- 31.12. aTyr Pharma Inc.
- 31.13. MediciNova Inc.
- 31.14. MitogenDx Inc.
- 31.15. arGentis Pharmaceuticals LLC
32. Global Scleroderma Diagnostics And Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Scleroderma Diagnostics And Therapeutics Market
34. Recent Developments In The Scleroderma Diagnostics And Therapeutics Market
35. Scleroderma Diagnostics And Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Scleroderma Diagnostics And Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Scleroderma Diagnostics And Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Scleroderma Diagnostics And Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34961_Scleroderma_Diagnostics_And_Therapeutics_GMR_2025
